Symbols / RVMD Stock $150.33 +2.06% Revolution Medicines, Inc.

Healthcare • Biotechnology • United States • NMS
RVMD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Mark A. Goldsmith M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 31.96B
Enterprise Value 30.49B
Income -1.37B
Sales —
FCF (ttm) -606.37M
Book/sh 7.49
Cash/sh 8.97
Employees 883
Insider 10d —
IPO Feb 13, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -26.41
PEG —
P/S —
P/B 20.06
P/C —
EV/EBITDA -22.12
EV/Sales —
Quick Ratio 6.59
Current Ratio 6.79
Debt/Eq 29.15
LT Debt/Eq —
EPS (ttm) -7.11
EPS next Y -5.69
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-06
ROA -37.53%
ROE -76.67%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 212.60M
Shs Float 194.18M
Insider Own 1.90%
Instit Own 95.49%
Short Float 6.36%
Short Ratio 3.12
Short Interest 12.80M
52W High 155.70
vs 52W High -3.45%
52W Low 34.00
vs 52W Low 342.15%
Beta 1.41
Impl. Vol. 64.04%
Rel Volume 0.74
Avg Volume 2.96M
Volume 2.20M
Target (mean) $184.45
Tgt Median $177.00
Tgt Low $165.00
Tgt High $263.00
# Analysts 20
Recom Strong_buy
Prev Close $147.30
Price $150.33
Change 2.06%
About

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$184.45
Mean price target
2. Current target
$150.33
Latest analyst target
3. DCF / Fair value
$-51.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$150.33
Low
$165.00
High
$263.00
Mean
$184.45

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main RBC Capital Outperform → Outperform $165
2026-05-07 main Guggenheim Buy → Buy $205
2026-05-07 main Wedbush Outperform → Outperform $165
2026-05-07 main Piper Sandler Overweight → Overweight $172
2026-05-07 main Needham Buy → Buy $183
2026-04-22 main Leerink Partners Outperform → Outperform $171
2026-04-22 reit HC Wainwright & Co. Buy → Buy $169
2026-04-20 reit Stifel Buy → Buy $215
2026-04-20 main Needham Buy → Buy $186
2026-04-14 main Wells Fargo Overweight → Overweight $167
2026-04-14 main RBC Capital Outperform → Outperform $162
2026-04-14 reit Wedbush Outperform → Outperform $147
2026-04-14 main Guggenheim Buy → Buy $175
2026-04-14 main Evercore ISI Group Outperform → Outperform $200
2026-04-14 main HC Wainwright & Co. Buy → Buy $169
2026-04-13 main Leerink Partners Outperform → Outperform $147
2026-04-13 main Oppenheimer Outperform → Outperform $165
2026-02-26 main Piper Sandler Overweight → Overweight $120
2026-02-26 main Wells Fargo Overweight → Overweight $144
2026-02-26 main Needham Buy → Buy $145
News
RSS: Latest RVMD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-27 MANCINI ANTHONY Officer — 3,120 $33.62 $104,894
2026-04-27 MANCINI ANTHONY Officer — 3,120 $131.66 $413,129
2026-04-15 GOLDSMITH MARK A Chief Executive Officer — 120,000 $4.09 $552,724
2026-04-15 GOLDSMITH MARK A Chief Executive Officer — 120,000 $150.09 $18,010,488
2026-03-25 MANCINI ANTHONY Officer — 37,450 $33.62 $1,259,069
2026-03-25 MANCINI ANTHONY Officer — 37,450 $93.22 $3,578,821
2026-03-19 CISLINI JEFFREY TODD General Counsel — 2,958 $97.44 $291,890
2026-03-17 GOLDSMITH MARK A Chief Executive Officer — 12,871 $99.48 $1,280,412
2026-03-17 ANDERS JACK LEE Chief Financial Officer — 2,753 $99.48 $273,870
2026-03-17 WANG XIAOLIN Officer — 2,010 $99.48 $199,956
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
11.58
-67.27%
35.38
Operating Revenue
0.00
0.00
-100.00%
11.58
-67.27%
35.38
Operating Expense
1,182.37
+71.48%
689.52
+38.25%
498.76
+69.84%
293.66
Research And Development
987.33
+66.72%
592.23
+39.96%
423.14
+67.20%
253.07
Selling General And Administration
195.04
+100.45%
97.30
+28.67%
75.62
+86.32%
40.59
General And Administrative Expense
195.04
+100.45%
97.30
+28.67%
75.62
+86.32%
40.59
Other Gand A
195.04
+100.45%
97.30
+28.67%
75.62
+86.32%
40.59
Total Expenses
1,182.37
+71.48%
689.52
+38.25%
498.76
+69.84%
293.66
Operating Income
-1,182.37
-71.48%
-689.52
-41.53%
-487.19
-88.63%
-258.28
Total Operating Income As Reported
-1,182.37
-71.48%
-689.52
-41.53%
-487.19
-88.63%
-258.28
EBITDA
-1,090.51
-85.14%
-589.02
-36.80%
-430.58
-73.19%
-248.62
Normalized EBITDA
-1,075.15
-81.20%
-593.35
-37.76%
-430.70
-73.23%
-248.62
Reconciled Depreciation
16.56
+40.04%
11.82
+27.02%
9.31
-3.59%
9.66
EBIT
-1,107.07
-84.25%
-600.85
-36.59%
-439.89
-70.32%
-258.28
Total Unusual Items
-15.36
-455.26%
4.32
+3659.13%
0.12
—
Total Unusual Items Excluding Goodwill
-15.36
-455.26%
4.32
+3659.13%
0.12
—
Net Income
-1,131.30
-88.52%
-600.09
-37.52%
-436.37
-75.46%
-248.71
Pretax Income
-1,131.30
-88.28%
-600.85
-36.59%
-439.89
-76.57%
-249.12
Net Non Operating Interest Income Expense
66.46
-23.50%
86.88
+82.98%
47.48
+418.70%
9.15
Interest Expense Non Operating
24.23
0.00
0.00
0.00
Net Interest Income
66.46
-23.50%
86.88
+82.98%
47.48
+418.70%
9.15
Interest Expense
24.23
0.00
0.00
0.00
Interest Income Non Operating
90.69
+4.39%
86.88
+82.98%
47.48
+418.70%
9.15
Interest Income
90.69
+4.39%
86.88
+82.98%
47.48
+418.70%
9.15
Other Income Expense
-15.39
-957.66%
1.79
+1054.79%
-0.19
—
Other Non Operating Income Expenses
-0.04
+98.54%
-2.53
-734.32%
-0.30
—
Gain On Sale Of Security
-15.36
-455.26%
4.32
+3659.13%
0.12
—
Tax Provision
0.00
+100.00%
-0.75
+78.63%
-3.52
-739.05%
-0.42
Tax Rate For Calcs
0.00
-100.00%
0.00
-84.34%
0.00
+300.00%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
0.01
+488.88%
0.00
0.00
Net Income Including Noncontrolling Interests
-1,131.30
-88.52%
-600.09
-37.52%
-436.37
-75.46%
-248.71
Net Income From Continuing Operation Net Minority Interest
-1,131.30
-88.52%
-600.09
-37.52%
-436.37
-75.46%
-248.71
Net Income From Continuing And Discontinued Operation
-1,131.30
-88.52%
-600.09
-37.52%
-436.37
-75.46%
-248.71
Net Income Continuous Operations
-1,131.30
-88.52%
-600.09
-37.52%
-436.37
-75.46%
-248.71
Normalized Income
-1,115.94
-84.63%
-604.41
-38.47%
-436.48
-75.50%
-248.71
Net Income Common Stockholders
-1,131.30
-88.52%
-600.09
-37.52%
-436.37
-75.46%
-248.71
Otherunder Preferred Stock Dividend
—
0.00
0.00
0.00
Diluted EPS
-5.95
-66.20%
-3.58
+7.25%
-3.86
-25.32%
-3.08
Basic EPS
-5.95
-66.20%
-3.58
+7.25%
-3.86
-25.32%
-3.08
Basic Average Shares
190.13
+13.35%
167.74
+48.24%
113.15
+40.34%
80.63
Diluted Average Shares
190.13
+13.35%
167.74
+48.24%
113.15
+40.34%
80.63
Diluted NI Availto Com Stockholders
-1,131.30
-88.52%
-600.09
-37.52%
-436.37
-75.46%
-248.71
Line Item Trend 2024-12-31
Total Assets
2,558.30
Current Assets
2,327.63
Cash Cash Equivalents And Short Term Investments
2,289.30
Cash And Cash Equivalents
543.06
Other Short Term Investments
1,746.23
Receivables
0.00
Accounts Receivable
0.00
Prepaid Assets
—
Other Current Assets
38.33
Total Non Current Assets
230.67
Net PPE
141.82
Gross PPE
163.65
Accumulated Depreciation
-21.82
Properties
0.00
Machinery Furniture Equipment
6.25
Construction In Progress
0.39
Other Properties
142.73
Leases
14.28
Goodwill And Other Intangible Assets
71.28
Goodwill
14.61
Other Intangible Assets
56.67
Non Current Prepaid Assets
12.13
Other Non Current Assets
5.44
Total Liabilities Net Minority Interest
293.10
Current Liabilities
163.91
Payables And Accrued Expenses
119.69
Payables
54.43
Accounts Payable
54.43
Current Accrued Expenses
65.26
Pensionand Other Post Retirement Benefit Plans Current
30.77
Current Debt And Capital Lease Obligation
12.87
Current Capital Lease Obligation
12.87
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
0.58
Total Non Current Liabilities Net Minority Interest
129.18
Long Term Debt And Capital Lease Obligation
122.97
Long Term Capital Lease Obligation
122.97
Non Current Deferred Liabilities
2.35
Non Current Deferred Revenue
—
Non Current Deferred Taxes Liabilities
2.35
Other Non Current Liabilities
0.67
Stockholders Equity
2,265.20
Common Stock Equity
2,265.20
Capital Stock
0.02
Common Stock
0.02
Preferred Stock
0.00
Share Issued
185.90
Ordinary Shares Number
185.90
Treasury Shares Number
0.00
Additional Paid In Capital
4,001.67
Retained Earnings
-1,737.80
Gains Losses Not Affecting Retained Earnings
1.32
Other Equity Adjustments
1.32
Total Equity Gross Minority Interest
2,265.20
Total Capitalization
2,265.20
Working Capital
2,163.72
Invested Capital
2,265.20
Total Debt
135.84
Capital Lease Obligations
135.84
Net Tangible Assets
2,193.93
Tangible Book Value
2,193.93
Derivative Product Liabilities
3.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-897.74
-61.05%
-557.44
-59.01%
-350.57
-56.23%
-224.40
Cash Flow From Continuing Operating Activities
-897.74
-61.05%
-557.44
-59.01%
-350.57
-56.23%
-224.40
Net Income From Continuing Operations
-1,131.30
-88.52%
-600.09
-37.52%
-436.37
-75.46%
-248.71
Depreciation Amortization Depletion
16.56
+40.04%
11.82
+27.02%
9.31
-3.59%
9.66
Depreciation
15.69
+45.87%
10.76
+30.51%
8.24
-4.03%
8.59
Amortization Cash Flow
0.87
-18.62%
1.07
+0.09%
1.07
-0.09%
1.07
Depreciation And Amortization
16.56
+40.04%
11.82
+27.02%
9.31
-3.59%
9.66
Amortization Of Intangibles
0.87
-18.62%
1.07
+0.09%
1.07
-0.09%
1.07
Other Non Cash Items
24.23
—
—
—
Stock Based Compensation
118.39
+49.49%
79.20
+28.21%
61.77
+98.01%
31.20
Operating Gains Losses
15.39
+465.99%
-4.21
-2617.96%
0.17
+778.95%
0.02
Gain Loss On Investment Securities
15.36
+455.26%
-4.32
-3859.13%
0.12
—
Gain Loss On Sale Of PPE
0.03
-72.88%
0.12
+126.92%
0.05
+173.68%
0.02
Change In Working Capital
86.82
+21284.98%
0.41
-98.90%
36.75
+372.46%
-13.49
Change In Receivables
0.00
-100.00%
1.25
-63.32%
3.42
+172.21%
1.26
Changes In Account Receivables
0.00
-100.00%
1.25
-63.32%
3.42
+172.21%
1.26
Change In Prepaid Assets
-21.69
-25.64%
-17.26
-250.12%
-4.93
-30.46%
-3.78
Change In Payables And Accrued Expense
121.80
+684.81%
15.52
-67.07%
47.14
+436.26%
8.79
Change In Accrued Expense
112.27
+410.65%
21.98
+49.88%
14.67
+876.56%
1.50
Change In Payable
9.54
+247.49%
-6.46
-119.91%
32.47
+345.51%
7.29
Change In Account Payable
9.54
+247.49%
-6.46
-119.91%
32.47
+345.51%
7.29
Change In Other Working Capital
—
-0.76
+90.89%
-8.37
+43.80%
-14.89
Change In Other Current Assets
-12.87
-862.56%
1.69
+94.02%
0.87
+138.72%
-2.25
Change In Other Current Liabilities
-0.42
-1172.73%
-0.03
+97.60%
-1.38
+47.48%
-2.62
Investing Cash Flow
118.06
+121.29%
-554.39
-61.82%
-342.60
-1320.63%
-24.12
Cash Flow From Continuing Investing Activities
118.06
+121.29%
-554.39
-61.82%
-342.60
-1320.63%
-24.12
Net PPE Purchase And Sale
-15.99
-55.12%
-10.31
-33.37%
-7.73
+28.54%
-10.82
Purchase Of PPE
-15.99
-55.12%
-10.31
-33.37%
-7.73
+28.54%
-10.82
Sale Of PPE
—
—
—
—
Capital Expenditure
-15.99
-55.12%
-10.31
-33.37%
-7.73
+28.54%
-10.82
Net Investment Purchase And Sale
134.05
+124.64%
-544.09
-62.48%
-334.87
-2417.81%
-13.30
Purchase Of Investment
-1,794.85
+16.00%
-2,136.62
-101.77%
-1,058.92
-72.81%
-612.77
Sale Of Investment
1,928.90
+21.12%
1,592.54
+119.95%
724.05
+20.78%
599.47
Financing Cash Flow
621.52
-35.22%
959.41
-21.95%
1,229.20
+307.79%
301.43
Cash Flow From Continuing Financing Activities
621.52
-35.22%
959.41
-21.95%
1,229.20
+307.79%
301.43
Net Common Stock Issuance
347.92
-58.89%
846.35
+119.40%
385.76
+29.43%
298.05
Proceeds From Stock Option Exercised
273.39
+142.41%
112.78
+1600.30%
6.63
+98.30%
3.35
Net Other Financing Charges
0.22
-22.54%
0.28
-99.97%
836.81
+1992300.00%
0.04
Changes In Cash
-158.16
-3.77%
-152.42
-128.43%
536.03
+913.00%
52.91
Beginning Cash Position
546.76
-21.80%
699.18
+328.55%
163.15
+48.00%
110.23
End Cash Position
388.60
-28.93%
546.76
-21.80%
699.18
+328.55%
163.15
Free Cash Flow
-913.73
-60.94%
-567.74
-58.45%
-358.30
-52.33%
-235.22
Amortization Of Securities
-27.83
+37.55%
-44.56
-100.70%
-22.20
-621.41%
-3.08
Common Stock Issuance
347.92
-58.89%
846.35
+119.40%
385.76
+29.43%
298.05
Issuance Of Capital Stock
347.92
-58.89%
846.35
+119.40%
385.76
+29.43%
298.05
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category